Biologically Focused Therapy of Treatment-Refractory MDS Patients
Trial ID or NCT#
Status
Purpose
This non interventional study examines the feasibility of using patient specific therapeutic screening method, ex vivo to enhance current treatment recommendations in a clinically feasible time frame of 30 days.
Official Title
Biologically Focused Therapy of Treatment Refractory MDS Patients
Eligibility Criteria
- * Provide informed consent;* Myelodysplastic syndrome as defined by WHO classification (see Appendix 2), or MDS/MPN with \>= 5% blasts in the bone marrow or peripheral blood, including chronic myelomonocytic leukemia (CMML) 1 and 2 by WHO classification* Relapsed/refractory disease, defined as failed or are ineligible for hypomethylating agent therapy* Cytogenetics reported
- * Hypoplastic MDS* Patients without adequate marrow samples for ex vivo analysis
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Jack Taw
650-723-2781
View on ClinicalTrials.gov